On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency (MHRA). DDW’s Megan Thomas evaluates the current impact of Brexit on the UK drug discovery sector in two parts: Part 1 and Part 2.
In these articles, you will learn about:
- The implications of leaving the EMA
- The UK’s access to Horizon Europe
- Updates on the Windsor Framework and Northern Ireland
- International trade deals with Switzerland
- The free trade agreement with the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP)
- An overview of where the UK currently stands
- Initiatives for innovation for UK scientists
- What’s next for the UK in a post-EU context.